Imperial College London
Alternate

ProfessorJesusGil

Faculty of Medicine, Institute of Clinical Sciences

Professor of Cell Proliferation
 
 
 
//

Contact

 

+44 (0)20 3313 8263jesus.gil

 
 
//

Location

 

ICTEM room 230ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Bousset:2022:10.1002/1878-0261.13312,
author = {Bousset, L and Gil, J},
doi = {10.1002/1878-0261.13312},
journal = {Molecular Oncology},
pages = {3855--3880},
title = {Targeting senescence as an anti-cancer therapy},
url = {http://dx.doi.org/10.1002/1878-0261.13312},
volume = {16},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Cellular senescence is a stress response elicited by different molecular insults. Senescence results in cell cycle exit and is characterised by multiple phenotypic changes such as the production of a bioactive secretome. Senescent cells accumulate during ageing and are present in cancerous and fibrotic lesions. Drugs that selectively kill senescent cells (senolytics) have shown great promise for the treatment of age-related diseases. Senescence plays paradoxical roles in cancer. Induction of senescence limits cancer progression and contributes to therapy success, but lingering senescent cells fuel progression, recurrence, and metastasis. In this review, we describe the intricate relation between senescence and cancer. Moreover, we enumerate how current anti-cancer therapies induce senescence in tumour cells and how senolytic agents could be deployed to complement anticancer therapies. "One-two punch" therapies aim to first induce senescence in the tumour followed by senolytic treatment to target newly exposed vulnerabilities in senescent tumour cells. "One-two punch" represents an emerging and promising new strategy in cancer treatment. Future challenges of "one -two punch" approaches include how to best monitor senescence in cancer patients to effectively survey their efficacy.
AU  - Bousset,L
AU  - Gil,J
DO  - 10.1002/1878-0261.13312
EP  - 3880
PY  - 2022///
SN  - 1574-7891
SP  - 3855
TI  - Targeting senescence as an anti-cancer therapy
T2  - Molecular Oncology
UR  - http://dx.doi.org/10.1002/1878-0261.13312
UR  - https://www.ncbi.nlm.nih.gov/pubmed/36065138
UR  - https://febs.onlinelibrary.wiley.com/doi/10.1002/1878-0261.13312
UR  - http://hdl.handle.net/10044/1/99530
VL  - 16
ER  -
Download